Format

Send to

Choose Destination
Genesis. 2016 Aug;54(8):439-46. doi: 10.1002/dvg.22949. Epub 2016 Jun 3.

Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice.

Author information

1
Department of Pharmacology, UNC Chapel Hill Medical School, Chapel Hill, North Carolina.
2
Neurotransgenic Laboratory, Duke University, Durham, North Carolina.

Abstract

DREADDs, designer receptors exclusively activated by designer drugs, are engineered G protein-coupled receptors (GPCR) which can precisely control GPCR signaling pathways (for example, Gq, Gs, and Gi). This chemogenetic technology for control of GPCR signaling has been successfully applied in a variety of in vivo studies, including in mice, to remotely control GPCR signaling, for example, in neurons, glia cells, pancreatic β-cells, or cancer cells. In order to fully explore the in vivo applications of the DREADD technology, we generated hM3Dq and hM4Di strains of mice which allow for Cre recombinase-mediated restricted expression of these pathway-selective DREADDs. With the many Cre driver lines now available, these DREADD lines will be applicable to studying a wide array of research and preclinical questions. genesis 54:439-446, 2016.

KEYWORDS:

G protein-coupled receptors; GsD; chemogenetic; hM3Dq; hM4Di

PMID:
27194399
PMCID:
PMC4990490
DOI:
10.1002/dvg.22949
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center